To support expanded access to new treatment options, SeattleNTC has participated in a wide variety of clinical trials across many indications.
DEPRESSION
Study Name: Usona uAspire
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults with Major Depressive Disorder.
Investigational Treatment: Psilocybin
Design: Randomized, multi-center, triple blinded, followed by open-label administrations during 1-year follow up.
Sponsor: Usona Institute
ClinicalTrials.gov ID NCT06308653
Study Name: SAINT ® OLO (Stanford Accelerated Intelligent Neuromodulation Therapy Open Label Optimization), a version of Transcranial Magnetic Stimulation
An Open-Label Optimization Study to Assess the Effectiveness of the SAINT Neuromodulation System to Treat Major Depressive Disorder.
Investigational Treatment: Accelerated protocol for TMS (Transcranial Magnetic Stimulation)
Design: Prospective, multi-center, open-label.
Sponsor: Magnus Medical
ClinicalTrials.gov ID NCT05819021
Study Name: COMPASS
A Phase III, multicentre, randomised, double-blind, controlled study to investigate the efficacy, safety, and tolerability of two initial administrations of COMP360 in participants with treatment-resistant depression.
Investigational Treatment: COMP360, version of psilocybin
Design: Randomized, multi-center, triple blinded, followed by a single additional randomized dose and a single open-label administration during 1-year follow up.
Sponsor: Compass Pathways
ClinicalTrials.gov ID NCT05711940
Study Name: Elumina AtaiBeckley
A Phase 2 Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Efficacy, Safety, and Tolerability of Repeated Doses of VLS-01 Buccal Thin Film in Participants with Treatment Resistant Depression
Investigational Treatment: VLS-01, version of DMT
Design: Randomized, multi-center, double-blinded.
Sponsor: AtaiBeckley
ClinicalTrials.gov ID NCT06524830
BIPOLAR DEPRESSION
Study Name: RECOVER VNS (Vagus Nerve Stimulation)
RECOVER: A Prospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VVNS Therapy System as a Adjunctive Therapy Versus a No Stimulation Control in Subjects with Treatment-Resistant Depression.
Investigational Treatment: Vagus Nerve Stimulation implant
Design: Randomized, multi-center, double-blinded, followed by open-label 4 years follow-up.
Sponsor: Alto Neuroscience
ClinicalTrials.gov ID NCT03887715
Study Name: ALTO-100-211
A Randomized, Double-Blind, Placebo-controlled Study Followed by Open-label Treatment of Alto-100 in Adults with Bipolar Disorder Currently Experiencing a Major Depressive Episode.
Investigational Treatment: ALTO-100
Design: Randomized, multi-center, double-blinded, followed by open-label.
Sponsor: Alto Neuroscience
ClinicalTrials.gov ID NCT06656416
GENERALIZED ANXIETY DISORDER
Study Name: MindMed/Definium VOYAGE
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120/DT120 Compared to Placebo in Generalized Anxiety Disorder.
Investigational Treatment: MM120/DT120, version of LSD
Design: Randomized, multi-center, double-blinded, followed by open-label.
Sponsor: Definium Therapeutics
ClinicalTrials.gov ID NCT06741228
POST-TRAUMATIC STRESS DISORDER
Study Name: Transcend IMPACT-2
An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD. Investigational Treatment: Methylone
Design: Randomized, multi-center, double-blinded.
Sponsor: Transcend Therapeutics
ClinicalTrials.gov ID NCT06215261
Study Name: MeRT-005-B
A Prospective, Double Blind, Randomized, Sham-Controlled, Clinical Trial to Evaluate the Safety and Efficacy of Biometrics-Guided Magnetic EEG Resonance Therapy (MeRT) Treatment of Post-Traumatic Stress Disorder.
Investigational Treatment: individualized, biometrics-guided Magnetic e-Resonance Therapy (MeRT), a version of Transcranial Magnetic Stimulation (TMS)
Design: Randomized, multi-site, double-blinded.
Sponsor: Wave Neuroscience
ClinicalTrials.gov ID NCT02990793
Study Name: Alto-100-001
Investigational Treatment: Alto-100
An Open-label Study of ALTO-100 in Adults With Major Depressive Disorder and/or Post-traumatic Stress Disorder.
Design: Open-label
Sponsor: Alto Neuroscience
ClinicalTrials.gov ID NCT05117632
BIOMARKER AND OBSERVATIONAL STUDIES
Study Name: VENTURA-RWE
Condition: Major Depressive Disorder with Anhedonia
A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNRI.
Design: Observational, biomarkers
Sponsor: Janssen Research & Development, LLC
ClinicalTrials.gov ID NCT05841030
Study Name: Kernel PREDICT
Condition: Major Depressive Disorder and Treatment-Resistant Depression
Prediction of REsponse to Depression Interventions using Clinical and TD-fNIRS measurements.
Design: Observational, biomarkers
Sponsor: Kernel
ClinicalTrials.gov ID NCT06002100
Study Name: Alto BEAM
Condition: Major Depressive Disorder
Establishment of EEG biomarkers for treatment of psychiatric disorders.
Design: Observational, biomarkers
Sponsor: Alto Neuroscience
WIRB Protocol #20193317
